Cited by 584Erythropoietin and Anemia TreatmentIron Metabolism and DisordersHemoglobinopathies and Related Disorders

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis

Open access

Chen, Nan, Hao, Chuanming, Peng, Xiaomei, Lin, Hongli, Yin, Aiping, Hao, Li, Tao, Ye, Liang, Xinling, Liu, Zhengrong, Xing, Changying, Chen, Jianghua, Luo, Laimin, Zuo, Li, Liao, Yunhua, Liu, Bi-Cheng, Leong, Robert, Wang, Chunrong, Liu, Cameron, Neff, Thomas, Szczech, Lynda, Yu, Kin-Hung P.·2019·New England Journal of Medicine

DOI 10.1056/nejmoa1813599

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Roxadustat (FG-4592) is an oral inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. In phase 2 studies involving patients with chronic kidney disease, roxadustat increased levels of endogenous erythropoietin to within or near the physiologic range, along with increasing hemoglobin levels and improving iron homeostasis. Additional data are needed regarding the efficacy and safety of roxadustat for the treatment of anemia in patients with chronic kidney disease who are not undergoing dialysis. METHODS: In this phase 3 trial conducted at 29 sites in China, we randomly assigned 154 patients with chronic kidney disease in a 2:1 ratio to receive roxadustat or placebo three times a week for 8 weeks in a double-blind manner. All the patients had a hemoglobin level of 7.0 to 10.0 g per deciliter at baseline. The randomized phase of the trial was followed by an 18-week open-label period in which all the patients received roxadustat; parenteral iron was withheld. The primary end point was the mean change from baseline in the hemoglobin level, averaged over weeks 7 through 9. RESULTS: During the primary-analysis period, the mean (±SD) change from baseline in the hemoglobin level was an increase of 1.9±1.2 g per deciliter in the roxadustat group and a decrease of 0.4±0.8 g per deciliter in the placebo group (P<0.001). The mean reduction from baseline in the hepcidin level (associated with greater iron availability) was 56.14±63.40 ng per milliliter in the roxadustat group and 15.10±48.06 ng per milliliter in the placebo group. The reduction from baseline in the total cholesterol level was 40.6 mg per deciliter in the roxadustat group and 7.7 mg per deciliter in the placebo group. Hyperkalemia and metabolic acidosis occurred more frequently in the roxadustat group than in the placebo group. The efficacy of roxadustat in hemoglobin correction and maintenance was maintained during the 18-week open-label period. CONCLUSIONS: In Chinese patients with chronic kidney disease who were not undergoing dialysis, those in the roxadustat group had a higher mean hemoglobin level than those in the placebo group after 8 weeks. During the 18-week open-label phase of the trial, roxadustat was associated with continued efficacy. (Funded by FibroGen and FibroGen [China] Medical Technology Development; ClinicalTrials.gov number, NCT02652819.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1813599

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Prevalence of Chronic Kidney Disease in the United States
Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895
HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia
Kim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
Self-citation
Prevalence of chronic kidney disease in China: a cross-sectional survey
Zhang, L., Wang, F., Wang, L., Wang, W., Liu, B., Liu, J., Chen, M., He, Q., Liao, Y., Yu, X., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60033-6 · Cited by 2,104
Self-citation
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Drüeke, T. B., Locatelli, F., Clyne, N., Eckardt, K., Macdougall, I. C., Tsakiris, D., Burger, H.-U., & Scherhag, A. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062276 · Cited by 2,094
Hepcidin and iron homeostasis
Ganz, T., & Nemeth, E. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.01.014 · Cited by 1,282
Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal Disease: Results of a Phase III Multicenter Clinical Trial
Eschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Regulation of Iron Metabolism by Hepcidin
Nemeth, E., & Ganz, T. (2006) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.26.061505.111303 · Cited by 756
Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs)
Peyssonnaux, C., Zinkernagel, A. S., Schuepbach, R. A., Rankin, E., Vaulont, S., Haase, V. H., Nizet, V., & Johnson, R. S. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31370 · Cited by 639

Flagged first, then by citations

Show all 32 references

Research works printed but not linked: 3

Zhu LN, Lv W, Teng J, et al. Association of residual renal function at initiation of dialysis with prognosis in maintenance dialysis patients. Chin J Nephrol 2012:757-764.
Collins AJ. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol Dial Transplant 2003;18:Suppl 2:ii2-ii6.12819293
KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3(1):1-150 (https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf).

Sorted by citations

Items 401–500 of 584

A new approach for anemia in kidney disease
Messa, P., & Cappellini, M. D. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.10.035 · Cited by 4
The Effect of Roxadustat on Transfusion-Dependent Myelodysplastic Syndrome Complicated by Chronic Kidney Disease
Hara, R., Gotō, N., Furuya, D., Kitahara, T., Numata, H., Watanabe, S., Kawada, H., & Ando, K. (2021) · Case Reports in Oncology · doi:10.1159/000519568 · Cited by 4
Production of functional recombinant prolyl hydroxylase-2 enzyme in insect cells for small molecule inhibitor screening studies
Guo, Z., Zi, J., Hao, Y., Li, Y., Liu, Z., Zhao, Q., Hao, L., & Diao, A. (2022) · Protein Expression and Purification · doi:10.1016/j.pep.2022.106073 · Cited by 4
Self-citation
Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia
Xu, T. Y., Ruan, Y., Liu, N., Wang, Y., Zang, X., Ma, Y., Qi, H., Mi, X., Yu, G., Zhang, C., et al. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2460726 · Cited by 3
Self-citation
Roxadustat for the Treatment of Early Post-Transplantation Anemia
Guenal, L., Gatault, P., Longuet, H., Maigret, L., Ferran, C., Larbi, L., Fillon, A., Halimi, J., Büchler, M., & Gueguen, J. (2025) · Transplant International · doi:10.3389/ti.2025.15033 · Cited by 3
Efficacy and safety of prolyl hydroxylase inhibitors for anemia in chronic kidney disease: a network meta-analysis
Niu, Y., Wang, T., Zhan, Y., Xu, H., Li, C., Hu, Z., He, J., Li, Y., & Fang, Y. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2616572 · Cited by 3
Beyond the horizon: emerging therapeutic approaches in myelodysplastic neoplasms
Merz, A. M. A., & Platzbecker, U. (2023) · Experimental Hematology · doi:10.1016/j.exphem.2023.11.004 · Cited by 3
A preliminary study of roxadustat in the treatment of aplastic anemia patients with inadequate erythroid responses
Shi, Y., Zhao, Y., Liang, W., Zhang, B., Kang, R., Yang, W., Zhao, X., & Zhang, F. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05799-5 · Cited by 4
Roxadustat enhances inflammation and metabolic reprogramming in human leukocytes by affecting oxygen sensing
Wrobeln, A., Schäper, T. M., Schild, Y., Kleine-Möllhoff, L., Leu, T., Jägers, J., Budeus, B., Heinrich, A., Sperber, H. S., Schwarzer, R., et al. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf167 · Cited by 3
Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor
Zhang, H., Huang, Z., He, L., Yuan, F., Sun, L., Liu, F., & Xiao, L. (2020) · Renal Failure · doi:10.1080/0886022x.2020.1803087 · Cited by 3
A distinctive distribution of hypoxia‐inducible factor‐1α in cultured renal tubular cells with hypoperfusion simulated by coverslip placement
Honda, T., Hirakawa, Y., Mizukami, K., Yoshihara, T., Tanaka, T., Tobita, S., & Nangaku, M. (2020) · Physiological Reports · doi:10.14814/phy2.14689 · Cited by 3
Anemia management: a historical perspective
Fishbane, S. N. (2021) · Kidney International Supplements · doi:10.1016/j.kisu.2020.12.004 · Cited by 3
Dysregulation of the sensory and regulatory pathways controlling cellular iron metabolism in unilateral obstructive nephropathy
Votava, J. A., Reese, S. R., Deck, K. M., Nizzi, C. P., Anderson, S. A., Djamali, A., & Eisenstein, R. S. (2021) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00537.2020 · Cited by 3
Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment
Bewersdorf, J. P., Xie, Z., & Zeidan, A. M. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000658 · Cited by 3
Safety and effectiveness of recombinant human erythropoietin coupled with different doses of Roxadustat for treatment of renal anemia in patients on maintenance hemodialysis.
Wei, S., Sun, J., Xu, K., Li, Y., & Zhang, Y. (2023) · PubMed Central · Cited by 3
Conventional and complementary alternative medicine therapies for renal anemia: a literature review
Lu, C.-M., Hsu, Y.-H., Lin, I.-H., Kuo, K., Liao, J.-F., Huang, H.-F., & Lu, P. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1342873 · Cited by 3
Hepcidin values can help predict the responsiveness of roxadustat for treating anemia in patients with chronic kidney disease
Murata, T., Fukuoka, T., Fujii, T., & Yujiri, T. (2025) · Laboratory Medicine · doi:10.1093/labmed/lmaf005 · Cited by 3
XVI Congress of the Italian Society of Experimental Hematology, Napoli, Italy, October 15-17, 2020
Authors, T. (2020) · Haematologica · doi:10.3324/haematol.2020.s2 · Cited by 3
Comparison of risk of peritoneal dialysis-associated peritonitis between roxadustat and recombinant human erythropoietin in peritoneal dialysis patients: a retrospective comparative cohort study
Zhang, W., Tan, Y., Ai, J., Luo, F., Su, X., Wu, Q., Su, L., Pan, J., Zheng, Q., Li, B., et al. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-5050 · Cited by 2
Self-citation
Prognostic impact of moderate to severe anemia associated with renal dysfunction in patients with heart failure
Noda, E., Matsushima, S., Hashimoto, T., Tsutsui, Y., Misumi, K., Enzan, N., Yoshida, K., Shinohara, K., Fujino, T., Katsuki, S., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-87650-z · Cited by 2
Stabilisation of HIF signalling in the mouse epicardium extends embryonic potential and neonatal heart regeneration
Gamen, E., Price, E., Pezzolla, D., Villiers, C. D., Gunadasa-Rohling, M., Lokman, A. B., Cosma, M.-A., Sayers, J., Silva, C. R., Salama, R. A., et al. (2025) · eLife · doi:10.7554/elife.107419.3 · Cited by 2
Comparative effectiveness of darbepoetin vs other agents in chronic kidney disease-related anemia: a systematic review and network meta-analysis
Hassan, M. F., Faheem, M. S. B., Cheema, S., Henna, F., Javid, S., Islam, M., Habib, I., Usman, M. A., Kurmasha, Y. H., Samadi, S., et al. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04557-7 · Cited by 2
The effect of SGLT2 inhibitor and HIF-PHI on the podocyte-specific molecules and cytoskeleton of diabetic podocytes
Li, C., Ng, J. K., Chan, G. C., Fung, W. W., Chow, K., & Szeto, C. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04677-0 · Cited by 2
A clinical study on roxadustat for anemia in diabetic nephropathy: a 8-week study
Jiang, L., Jia, R., Zheng, Z., Zhang, X., Xu, Y., Raj, A., & Sun, D. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03757-0 · Cited by 2
Short-term effect of low-dose roxadustat combined with erythropoiesis-stimulating agent treatment for erythropoietin-resistant anemia in patients undergoing maintenance hemodialysis
Xu, Q., Huang, J., Liu, Q., Wang, X., Liu, H., Song, Y., Dou, F., Lv, S., & Liu, G. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1372150 · Cited by 2
Advances in the management of chronic kidney disease – a South African perspective
Jardine, T., Davids, M. R., & Chothia, M.-Y. (2024) · Wits Journal of Clinical Medicine · doi:10.18772/26180197.2024.v6n2a6 · Cited by 2
Optimizing the dosing regimen of roxadustat in kidney transplant recipients with early post-transplant anemia
Shen, Z., Yang, X.-Y., Han, L., Yang, X., Xie, J., Liu, X., Mao, J., Dai, H., Kong, W.-W., Wu, X., et al. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.09.004 · Cited by 2
Study on HIF-PHI combined with iron supplement in treatment of renal anemia in rats
Gao, Z., Gao, Y., Wang, Q., Wang, Q. M., Lu, P., Lv, H., Xue, H., Ma, X., Li, S., & Hu, Z. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04045-y · Cited by 2
Roxadustat effectiveness versus ESAs in peritoneal dialysis patients during the COVID-19 pandemic: A retrospective study
Liu, J., Zhou, K., Chen, M., Liu, Z., Huang, R., Waheed, Y. A., Yang, F., Liu, K., Zhao, J., Zhang, L., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0320536 · Cited by 2
Self-citation
Recent advance of hypoxia-inducible factor prolyl hydroxylases inhibitors for anemia therapy
Wang, D., Zhao, W., Wang, Y., Ni, S., Feng, C., & Yao, S. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117907 · Cited by 2
RETRACTED: Roxadustat for CKD Anemia – Starting the Jigsaw Puzzle, What Will the Finished Picture Show?
Winkelmayer, W. C., & Walther, C. P. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.01.035 · Cited by 2
Retracted
Anaemia and chronic kidney disease
Rumjon, A. (2023) · Medicine · doi:10.1016/j.mpmed.2022.12.009 · Cited by 2
Roxadustat as treatment for a blood transfusion-dependent maintenance hemodialysis patient: A case report and review of literature
Fei, M., Wen, X.-Q., Yu, Z., Kang, T., Wu, W., & Ou, S. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i15.3680 · Cited by 2
Does HIF-PHI increased risk of gastrointestinal hemorrhage in patients with renal anemia: a review of cases reported to the U.S. Food and drug administration adverse event reporting system
Zhou, Y., Ren, Q., Hu, R., Zheng, K., Qin, Y., & Li, X. (2021) · Renal Failure · doi:10.1080/0886022x.2021.1952881 · Cited by 2
A Single Arm Clinical Study on the Effects of Continuous Erythropoietin Receptor Activator Treatment in Non-Dialysis Patients with Chronic Heart Failure and Renal Anemia
Sezai, A., Sekino, H., Taoka, M., Osaka, S., & Tanaka, M. (2023) · Biomedicines · doi:10.3390/biomedicines11030946 · Cited by 2
Ambulante Anämiediagnostik und -therapie
Tesch, H., Steinmetz, H. T., & Link, H. (2023) · AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie · doi:10.1055/a-1789-1241 · Cited by 2
Hypoxia-inducible factors and essential hypertension: narrative review of experimental and clinical data
Afşar, B., & Afşar, R. E. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00497-x · Cited by 2
Clinical effect of roxadustat vs. erythropoietin in non-dialysis CKD with diabetes: a single center propensity score matching analysis
Chen, J., Ren, Y., Wang, M., Hu, X., Shang, Y., Li, Y., Zhu, B., He, Q., & Shao, L. (2024) · International Urology and Nephrology · doi:10.1007/s11255-024-03983-0 · Cited by 3
Self-citation
Strategies for Managing Anemia in Chronic Kidney Disease
Biju, B., D’cruz, A., Jiby, S., Devassy, M., & Jacob, R. (2024) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v14i4.6501 · Cited by 2
Prevalence, associated factors and cardiocerebral vascular prognosis of anaemia among patients on chronic haemodialysis in South Guangdong, China
Liang, M., Wu, Y., Su, N., Liu, Y., Lin, W., Li, S., Zhong, W., & Jiang, Z. (2020) · Journal of International Medical Research · doi:10.1177/0300060520965791 · Cited by 2
Novel treatment options for chronic kidney disease complications
Foresto, R. D., & Pestana, J. O. M. (2020) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.66.s1.1 · Cited by 2
The evolving science of anemia management in chronic kidney disease
Massy, Z. A., & Drüeke, T. B. (2021) · Kidney International Supplements · doi:10.1016/j.kisu.2020.11.002 · Cited by 2
TP0463518 (TS-143) Ameliorates Peptidoglycan-Polysaccharide Induced Anemia of Inflammation in Rats
Kato, S., Yamamoto, K., Uchida, S., & Takahashi, T. (2021) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00038 · Cited by 1
Different Effects of Hypoxia-Inducible FactorProlyl Hydroxylase Inhibitors on Serum Lipid Levels in Patients on Hemodialysis
Taira, T., Sugita, A., Oda, G., Kurata, M., Hisa, Y., Hasegawa, M., Azuma, K., Chiba, T., & Yoshimura, S. B. A. A. (2024) · Journal of Urology and Renal Diseases · doi:10.29011/2575-7903.001362 · Cited by 1
Modern strategies of hemotransfusiology and alternatives to blood transfusion
Holbreich, V. A., Maskin, S. S., Matyukhin, V. V., Николаевич, К. И., & Владимирович, А. В. (2024) · Journal of Volgograd State Medical University · doi:10.19163/1994-9480-2024-21-2-12-20 · Cited by 1
Evaluation of hypoxia-inducible factor-1α and urine non-transferrin-bound iron concentrations in cats with chronic kidney disease
Chen, C.-H., Hsu, W., Tsai, P., Lai, C., Wu, M., & Lee, Y. (2024) · Frontiers in Veterinary Science · doi:10.3389/fvets.2024.1482998 · Cited by 1
Is Roxadustat Responsible for the Jaundice of a Dialysis Patient with β-Thalassemia? A Case Report
Zhou, H.-S., Huang, H.-W., Xu, H., Xiao, G., & Yuan, Q. (2025) · Springer eBooks · doi:10.1007/978-981-97-7636-8_26 · Cited by 1
Roxadustat promotes allograft recovery after kidney transplantation: A prospective, multicenter, randomized controlled trial
Ma, M., Han, F., Zhang, L., Huang, Z., Zhang, T., Li, H., Fang, J.-L., Chen, Z., & Na, N. (2025) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2025.02.041 · Cited by 1
The ROX@PDA@PCL vascularized bionic nerve conduit facilitates the restoration of nerve defects
Lin, D., Peng, J., Zhang, Y., Wang, X., Xu, X., & Jia, J. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1561177 · Cited by 1
Roxadustat for ESA ‐Hyporesponsive Renal Anemia in a 13‐Year‐Old on Hemodialysis: Case Report and Mini‐Review
Zhang, M., Guo, Y., Zhu, Y., & Yang, J. (2025) · Clinical Case Reports · doi:10.1002/ccr3.70985 · Cited by 1
Hypoxia-inducible factor 2α overexpression in podocytes ameliorates lipid metabolism disorders in diabetic kidney disease by inhibiting S1P
Yang, X., Wang, Q., Nie, H., Wang, M., Wang, Y., Li, S., Liu, Q., & Liu, G. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2568972 · Cited by 1
Global research trends in renal anemia: a multidimensional bibliometric study
Niu, Y., Wang, Y., Huo, C., & Fang, Y. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2580457 · Cited by 1
Effects of Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors on Relationship Between B‐Type Natriuretic Peptide and Hemoglobin Levels in Patients With Cardiorenal Anemia Syndrome
Yoshitake, T., Hashimoto, T., Matsushima, S., Ikuta, K., Yamamoto, S., Suenaga, T., Nakashima, S., Kai, T., Misumi, K., Shinohara, K., et al. (2025) · Cardiovascular Therapeutics · doi:10.1155/cdr/3143864 · Cited by 1
Sex-Specific Impact of Roxadustat on Residual Kidney Function in Peritoneal Dialysis Patients: A Propensity Score-Weighted Analysis
Jiang, S., Zhang, G., Xu, Y., Li, Y., Li, G., Li, H., Liu, Y., Li, S., Lin, J., Guo, Q., et al. (2025) · Kidney Medicine · doi:10.1016/j.xkme.2025.101208 · Cited by 1
Prolyl hydroxylase inhibitors, roxadustat and daprodustat, inhibit platelet activation and thrombosis through the PI3K/AKT/HIF-1α pathway
Yuan, Y., Yang, Z., Guo, F., Liu, T., Li, Q., Wen, K., Liu, G., Zhou, Y., & Zhou, Y. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117808 · Cited by 1
Protective and pathogenic: The Janus-faced role of cGAS–STING in the brain
Corona, C., Kanzlemar, C., Hussaini, S. A., & Ratan, R. R. (2026) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x261427904 · Cited by 1
Enarodustat combined with oral iron supplementation for iron-deficient non-dialysis-dependent chronic kidney disease anemia patients: Synergistic effects and safety
Lu, Y., & Jiang, G. (2026) · Medicine · doi:10.1097/md.0000000000048101 · Cited by 1
Hypoxia inducible factor network reflects kidney disease progression in diabetes and sodium-glucose co-transporters inhibition
Nair, V., Minakawa, A., Smith, C., Berthier, C. C., Hartman, J., Menon, R., Fermin, D., Otto, E. A., Gisch, D. L., Eadon, M. T., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02653-0 · Cited by 1
Activation of the HIF1α Pathway in Neurologic Disease: A Targetable Master Regulator to Reduce Neuropathology
Thelwell, J., & Johnson, A. J. (2026) · Neuroglia · doi:10.3390/neuroglia7030018 · Cited by 1
Impact of HIF-prolyl hydroxylase inhibitors on VEGF expression and vascular adverse events in chronic kidney disease: a meta-analysis of 34 randomized controlled trials
Montazer, S. M., Asadi, A., Taghipour, A., Rajabi, A., Shabanian, A., Daraei, M., Bahmani, A., Bay, M. J., & Karimi, M. (2026) · Journal of Nephrology · doi:10.1093/joneph/aajag065 · Cited by 1
Roxadustat-associated cholestatic jaundice in haemodialysis patients with positive rechallenge
Ke, X., & Liu, C. (2026) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2026_007262 · Cited by 1
Self-citation
Impaired liver-muscle lactate metabolism causes sarcopenia via lactic acidosis in skeletal muscle in mice
Eguchi, T., Hayashiji, N., Tabata, S., Kabetani, K., Shintani, Y., Makinoshima, H., & Ito, N. (2026) · Science Advances · doi:10.1126/sciadv.aeb4011 · Cited by 1
Evaluation and Management of Anemia in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2026 Clinical Practice Guideline
Hedayati, S. S., Babitt, J. L., Berns, J. S., Bozkurt, B., Cheung, R. S., Effa, E., Effa, E. E., Eisenga, M. F., Fishbane, S., Ginzburg, Y. Z., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-02326 · Cited by 1
New Approaches for Anemia in MDS
Platzbecker, U. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(20)30463-8 · Cited by 1
Going in Early: Hypoxia as a Target for Kidney Disease Prevention in Diabetes?
Barrett, H. L., Donaghue, K. C., & Forbes, J. M. (2020) · Diabetes · doi:10.2337/dbi20-0037 · Cited by 1
Heterogeneity of Fibroblasts in Healthy and Diseased Kidneys
Yoshikawa, T., Sato, Y., & Yanagita, M. (2021) · Biochemistry · doi:10.5772/intechopen.99492 · Cited by 1
Nutrition and anemia in chronic kidney disease
Wang, A. Y.-M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818540-7.00035-5 · Cited by 1
Hypoxia-inducible factor prolyl hydroxylase inhibitors in kidney transplant recipients
Ogata, M., Miyauchi, T., Sakurai, Y., Murata, M., Shinoda, K., Shibagaki, Y., & Yazawa, M. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac015 · Cited by 1
Exploring Mechanisms by Which Danggui Buxue Decoction Regulates Inflammation and Improves Renal Anemia Based on Network Pharmacology
Tu, C., Huang, G., Li, C., Li, C., Min, Y., Li, H., Mao, D., & Xiong, F. (2022) · Natural Product Communications · doi:10.1177/1934578x221093905 · Cited by 1
Lower starting dose of roxadustat in non-dialysis-dependent chronic kidney disease patients with anaemia: a study protocol for a randomised, multicentre, open-label study
Li, P., Sun, X., Chen, D., Lin, H., Zhang, L., Wu, Y., Pan, S., Cai, G., & Chen, X. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-068864 · Cited by 1
Self-citation
Management of Anemia in Renal Palliative Care Clinic: A Patient-Centered Approach
Cheng, H. W. B., Chan, K. P., Chung, W. K. V., Hsu, Y., & Chan, K. Y. (2024) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2024.01.002 · Cited by 1
Targeting anemia in myeloid neoplasms
Gangat, N., & Tefferi, A. (2024) · American Journal of Hematology · doi:10.1002/ajh.27408 · Cited by 1
The clinical efficacy of combined ESA and Roxadustat treatment for renal anemia in hemodialysis patients with secondary hyperparathyroidism: A case series
Zhong, J.-J., Wang, M., Zheng, G.-F., Li, M.-P., & Chen, D.-Z. (2024) · Medicine · doi:10.1097/md.0000000000039083 · Cited by 1
Discovery of Novel, Potent, Orally Bioavailable and Efficacious, Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for Hematopoietic Stem Cell Mobilization
Wu, M., Koester, D. C., Walkinshaw, G., Ng, D., 周小体, Ho, A., Tsao, J., Barnes, M., Brenner, M. C., Spong, S. M., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02889 · Cited by 1
Rationale Diagnostik und Therapie der Anämie
Steinmetz, H. T., & Steinmetz, G. F. L. (2020) · best practice onkologie · doi:10.1007/s11654-020-00216-5 · Cited by 1
Evaluation of 3-carbamoylpropanoic acid analogs as inhibitors of human hypoxia-inducible factor (HIF) prolyl hydroxylase domain enzymes
Chong, M., Toh, L., Tumber, A., Chan, Y. Y., Chan, M. C., Abboud, M. I., Schofield, C. J., & Yeoh, K. K. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02681-7 · Cited by 1
Management of Anemia in Peritoneal Dialysis Patients
Gupta, N., & Wish, J. B. (2023) · Springer eBooks · doi:10.1007/978-3-030-62087-5_45 · Cited by 1
Adipocyte-specific deletion of the oxygen-sensor PHD2 sustains elevated energy expenditure at thermoneutralityPreprint
Gomez-Salazar, M. A., Cervera, I. P., Wang, R., French, K. L., García-Martín, R., Blüher, M., Schofield, C. J., Stimson, R. H., Chavakis, T., Gudmundsson, E. F., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.05.425401 · Cited by 1
Burden of renal anemia in 204 countries and territories, 1990-2021 : results from the Global Burden of Disease Study 2021Preprint
Chu, F., Ji, J., Ma, Y., Guan, Q., Chen, L., Chen, Z., Ji, Q., Sun, M., Zhang, H., Huang, T., et al. (2024) · medRxiv · doi:10.1101/2024.03.12.24304162 · Cited by 1
Cellular oxygen sensing and the anesthesiologist: the Nobel-worthy discovery of hypoxia inducible factor and its implications in clinical practice
Hare, G. M. T. (2019) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-019-01526-1
Ein Gespür für Sauerstoff: Entdeckung des molekularen Mechanismus der zellulären Sauerstoffregulation rückt die Hydroxylierung von Makromolekülen in den Blickpunkt
Loenarz, C. (2020) · Angewandte Chemie · doi:10.1002/ange.201913263
Prolyl-hydroxylase domain inhibitors in chronic kidney disease, a promising alternative for erythropoiesis-stimulating agent
Rubinsztajn, A., & Fouque, D. P. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.04.033
Letter to the Editor in response to the article “Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis”
Farag, Y. M. K., Zheng, Z., & Luo, W. F. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105213
Clinical perspectives on the treatment of renal anemia with HIF stabilizers
Kuriyama, S., Yaginuma, T., Hirao, M., & Kawaguchi, Y. (2020) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.53.493
A new paradigm in treating patients with chronic kidney disease and anaemia after a journey lasting more than 35 years
Locatelli, F., & Vecchio, L. D. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab177
Pelabuhan ferry di Gorontalo
Utamin, I. (2006)
Stabilisation of HIF signalling in the epicardium extends embryonic potential and neonatal heart regenerationPreprint
Gamen, E., Price, E. L., Pezzolla, D., Villiers, C. D., Gunadasa-Rohling, M., Salama, R. A., Mole, D. R., Bishop, T., Pugh, C. W., Choudhury, R. P., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-569151/v1
Roxadustat for renal patients with hyporesponsiveness to ESAs: a new opportunity?
Paoletti, E., Bussalino, E., & Ravera, M. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02794-w
Evaluation and replacement of renal function: history, advancement, and challenges
Cai, Y., & LiMeng, C. H. E. N. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0182
NOBEL 2019 - A NEW ALTERNATIVE TO BLOOD TRANSFUSIONS
Жибурт, Е. Б., & Kuznecov, S. I. (2019) · Bulletin of Pirogov National Medical & Surgical Center · doi:10.25881/bpnmsc.2020.55.86.022
Therapie der renalen Anämie
Emrich, I. E., Böhm, M., & Heine, G. H. (2021) · Dialyse aktuell · doi:10.1055/a-1402-8805
Treating anemia in chronic kidney disease. ¿An ongoing revolution?
Ortíz, A., & Sánchez-Niño, M. D. (2021) · ANALES RANM · doi:10.32440/ar.2021.138.02.ed01
Anemia in Chronic Kidney Disease
Cantarin, M. P. M., & Outschoorn, U. E. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-83082-3_13
Identification and analysis of genetic and chemical modulators of iron metabolism
Hawula, Z. J. (2021) · Queensland University of Technology · doi:10.5204/thesis.eprints.225904 · Cited by 1
FG-4592 Protects the Intestine from Irradiation-Induced Injury by Targeting TLR4 Signaling PathwayPreprint
Feng, Z., Xu, Q., He, X., Wang, Y., Fang, L., Zhao, J., Cheng, Y., Liu, C., Du, J., & Cai, J. (2022) · Research Square · doi:10.21203/rs.3.rs-1435106/v1
Self-citation
The efficacy and safety of roxadustat in anemia treatment in hemodialysis patients with erythropoietin-hyporesponsivenessPreprint
Zou, Y., Chang, D., Wang, Y., He, J., Li, M., Cai, Y., Wei, J., Yang, D., He, D., Lei, M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1516910/v1
Role of HIF-PHD inhibitor in improving adherence and safety in the treatment of anemia in chronic kidney disease
Ferris, I. L., & Serrano-Alonso, M. (2022) · Anales del Sistema Sanitario de Navarra · doi:10.23938/assn.0992
Design and Methodology of the Impact of Roxadustat on Left Ventricular Hypertrophy in Hemodialysis Patients (ROFIH-HD): A Multicenter, Prospective, Randomized Controlled TrialPreprint
Tan, W., Tian, E., Tang, B., Zhong, L., Hua, W., Jiang, X.-H., Li, Z., Sun, Y., Hao, Y., He, J. W., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4061362
The effect of intra- and extracellular challenges on cellular responses in atherosclerosis
van Kuijk, K. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20210604kk
Author response: Repression of hypoxia-inducible factor-1 contributes to increased mitochondrial reactive oxygen species production in diabetes
Zheng, X., Narayanan, S., Xu, C., Angelstig, S. E., Grünler, J., Zhao, A., Toro, A. D., Bernardi, L., Mazzone, M., Carmeliet, P., et al. (2022) · eLife · doi:10.7554/elife.70714.sa2

Authors: Chen, N., Hao, C., Peng, X., Lin, H., Yin, A., Hao, L., Tao, Y., Liang, X., Liu, Z., Xing, C., Chen, J., Luo, L., Zuo, L., Liao, Y., Liu, B.-C., Leong, R., Wang, C., Liu, C., Neff, T., Szczech, L., & Yu, K.-H. P.
Affiliations: Shanghai Jiao Tong University (CN)
From the Department of Nephrology, Institute of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (N.C.), and the Division of Nephrology, Huashan Hospital Fudan University (C.H.), Shanghai, the Department of Nephrology, People’s Hospital of Guangxi Zhuang Autonomous Region (X.P.), and the Department of Nephrology, First Affiliated Hospital of Guangxi Medical University (Y.L.), Nanning, the First Affiliated Hospital of Dalian Medical University, Dalian (H.L.), the...
ORCID: Chen, Nan
Lin, Hongli
Tao, Ye
Liang, Xinling
Liu, Zhengrong
Chen, Jianghua
Luo, Laimin
Zuo, Li
Liao, Yunhua
Liu, Bi-Cheng
Wang, Chunrong
Yu, Kin-Hung P.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2019-09-12
Volume: 381
Issue: 11
Pages: 1001-1010
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1813599
OpenAlex: W2963534431
Cited by: 582
References: 32
Citations by year: 2026: 53 · 2025: 62 · 2024: 68 · 2023: 68 · 2022: 96 · 2021: 112 · 2020: 100 · 2019: 22
FWCI: 58.49
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: FibroGen
Topics: Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
Keywords: roxadustat, chronic kidney disease, anemia of chronic kidney disease, HIF prolyl hydroxylase inhibitors, non-dialysis patients, hemoglobin increase, hepcidin, iron metabolism, erythropoiesis, hyperkalemia, metabolic acidosis, total cholesterol, Chinese patients, open-label extension
MeSH terms: Acidosis, Adult, Aged, Anemia, Cholesterol, Double-Blind Method, Female, Glycine, Hematinics, Hemoglobins, Humans, Hyperkalemia, Isoquinolines, Male, Middle Aged, Renal Insufficiency, Chronic, Hypoxia-Inducible Factor-Proline Dioxygenases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks